Masonic Cancer Center, University of Minnesota: Neoplasms trials
The registry lists 14 Neoplasms studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 0 are open to participants now and 5 have results posted.
Early Phase 1 1Phase 1 5Phase 2 5Phase 3 1No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT05708924Phase 1Results posted
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCTCompletedNCT02988466Phase 2Results posted
- Pilot Study of Multi-Modality Imaging in Patients With Hematologic MalignanciesTerminatedNCT02042924Not applicableResults posted
- Stem Cell Transplantation for Hematological MalignanciesTerminatedNCT00176839Phase 2/3Results posted
- Effect of Kava on Anxiety and Stress in Cancer SurvivorsWithdrawnNCT06213298Early Phase 1
- EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy ToxicityCompletedNCT05809557Not applicable
- Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer SurvivorsActive, not recruitingNCT05665543Not applicable
- Study of CD133KDEL Toxin in the Treatment for Solid TumorsWithdrawnNCT02845414Phase 1
- Treg Cells for AGVHD in Non-myeloablative UCB TransplantWithdrawnNCT02118311Phase 2
- Safety of Romiplostim (Nplate®) Following UCBTCompletedNCT02046291Phase 1
- Auto Transplant for High Risk or Relapsed Solid or CNS TumorsCompletedNCT01505569Not applicable
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid TumorsTerminatedNCT00003926Phase 1